United States Patent and Trademark Office
- Sales Receipt -

12/29/2005 DWILLIA4 00000001 022117 10731815

01 FC:1201 200.00 DA

Serial No. 10/731,815

Attorney Docket 52143BUSM1

RECEIVED IN THE UNITED STATES PATENT AND TRADEMARK OFFICEENTRAL FAX CENTER

SEP 2 7 2005

In re Application of

Judi BRYANT et al.

Serial No. 10/731,815

Filed December 09, 2003

: Group Art Unit 1624

: Examiner Emily B. BERNHARDT

Platelet Adenosine Diphosphate Receptor Antagonists

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

I hereby certify that this correspondence is being facsimile transmitted to the USPTO's central facsimile number at

the date below.

Signature

Sir:

RESPONSE UNDER 37 CFR 1.111

In response to the Office Action mailed June 27, 2005, Applicants respectfully request reconsideration of the claimed subject matter in light of the following Amendments to the Claims and Remarks.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this paper.

Remarks begin on page 22 of this paper.

Serial No. 10/731,815

Attorney Docket 52143BUSM1

CONCLUSION

The Office Action dated June 27, 2005 has been carefully considered. It is believed that the amendments submitted herewith and the above comments represent a complete response to the Examiner's rejections and place the present application in condition for allowance. Reconsideration is respectfully requested.

Respectfully submitted,

Werun L. Washtien
Wendy L. Washtien
Patent Agent for Applicants
Registration No. 36,301

Berlex Pharmaceuticals
Corporate Patents
2600 Hilltop Drive
P.O. Box 4099
Richmond, California 94804-0099
Telephone: (510)-669-4483

Fax:

(510)-262-7095

03/23/2000 TUE 14:23 FAX 510 262 7095 Berlex Biosciences +++ USPTO Hissing Parts

03/23/2004 TUE 1

PTO/SB/17 (10-03)
Approved for use through 07/31/2006, OMB 0851-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are regular,	d to respon	of to a collection of info	edertain Unide; U.S. DEPARTMENT OF medon unides it displays a valid OMS co	nirol number.
FEE TRANSMITTAL		Co	omplete if Known	
		plication Number	10/731,815	
for FY 2004 . Effective 10/01/2003, Patent fees are subject to canval revision.		ng Date	December 9, 2003	
		st Named Inventor	Judi Bryant et al.	
	ex:	aminer Name	Nat yet known	
Applicant claims small entity status. See 37 CFR 1.27	- Ari	Unit	1614	
TOTAL AMOUNT OF PAYMENT (\$) 130.00	Ath	omey Docket No.	52143BUSM1	
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)			
	3. ADDITIONAL FEES			
Doposil Account:	Large Entity Small Entity Foo Poo Fee Fee Pee Cescription			
Deposit Account 02-2117	Code (\$)	Code (S)		Fee Paid 130.00
Number Deposit	1051 13		harge - late filing fee or ceth harge - late provisional filing foo or	130,00
Account Name Berlex Biosciences		gove	rsheet	
he Director is authorized to: (check all that apply)	1053 13 1812 2.5		English specification iling a request for ex parte reexamination	
Charge feets indicated below Credit any overpsyments Charge any additional feats) or any underpayment of feets		20" 1804 920" Requ	uesting publication of SIR prior to	
Charge any additional fea(s) or any underpayment of fea(c) Charge fea(s) indicated below, except for the filing fee	1805 1.84	Exam	viner action vesting publication of SIR after	
the above-identified deposit account.		Exam	miner action	
FEE CALCULATION			ension for reply within first month	
. Basic filing fee	1252 4:		ansion for raply within third month	
arge Entity Small Entity on Fou Fun Fee Paid Fee Paid	1254 1,41		ension for reply within fourth month	
ode (6) Cade (5) 001 770 2001 385 Utility filing fee	1255 2.0		ension for reply within fifth month	
002 340 2002 170 Design filing fee	1401 3	30 2401 165 Notic	ice of Appeal	
003 530 2003 286 Plant filing fee	1402 3	30 2402 165 Filin	g a brief in support of an appeal	
004 770 2004 385 Reissue Eling fee			uest for oral hearing	
005 160 2005 80 Provisional filing fee	1451 1,5		tion to institute a public use proceeding	
SUBTOTAL (1) (5)	1453 1.3		tion to revive - unavaidable	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501 1.3	1	ly issue fee (or reissue)	
Extra Claims Pee from Fee Paid			ign leave fee	
Total Claims X = -20~ × X = -			ni istuo fee	
Ctains -3 B A A B A A A A A A A A A A A A A A A			licons to the Commissionar	
Large Entity : Small Entity		1	cossing fee under 37 CFR 1.17(q)	
Fee Fee Fee Fee Pee Description Code (8) Code (9)	***		mission of information Disclosure Strat ording each patent assignment per	
1202 18 2202 9 Claims in excess of 20		prop	sent frames unumber or burbainsmit	
1201 86 2201 43 Independent daims in excess of \$	1809 7		ng a submission after final rejection CFR 1,129(p))	
1203 290 2203 145 Multiple dependent claim, if not poid 1204 86 2204 43 ** Reissue independent claims	1810 7		each additional invention to be mined (37 CFR 1.129(b))	
1204 88 2204 43 Persiste averant cisms over original patent	1801 7		quest for Continued Examination (RCE)	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original calord	1802 900 1802 900 Request for expedited examination of a design application			
SUBTOTAL (2) (\$) Other fee (specify)				
"or number previously peid, if graster; For Relatives, see above Reduced by Basic Filing Fee Peid SUBTOTAL (3) (\$) 130.00				
SUBMITTED BY (Complete (3 applicable))				
Name (Athermotypos Ronald S. Hermenau Registration No. 34,620 Tetaphone (510) 869-4483				3
Signature Kongly & House		The state of the s	Date 3 23 (04

WARNING: Information on this form may become public, Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or ratefu a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradomark Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you mod assistance in completing the form, cell 1-800-PTO-9199 and select option 2.